DFTX / Definium Therapeutics, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Corporate Presentation May 2026

Corporate Presentation May 2026 This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (C

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MA

Exhibit 99.1 Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on positive Phase 2b study results

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (C

EX-99.1

Exhibit 99.1 Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into 2028 Conferenc

Equity Compensation Initial grants to newly appointed directors

Exhibit 10.2 Definium Therapeutics, Inc. Non-Employee Director Compensation Policy As amended on April 15, 2026 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Definium Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Di

Part Ii - OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Definium T

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (C

DEFINIUM THERAPEUTICS, INC. 2025 equity incentive plan PERFORMANCE SHARE Unit Agreement COVER SHEET

Exhibit 10.1 DEFINIUM THERAPEUTICS, INC. 2025 equity incentive plan PERFORMANCE SHARE Unit Agreement COVER SHEET Definium Therapeutics, Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants performance share units (the “PSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subjec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th

Investor & Analyst Day April 22, 2026

Investor & Analyst Day April 22, 2026 This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing an

Exhibit 99.1 04.22.26 Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patients with topline data readout on track for early 3Q 2026; Pano

DEFINIUM THERAPEUTICS, INC. INDUCEMENT GRANT PERFORMANCE SHARE Unit Agreement COVER SHEET

Exhibit 10.24 DEFINIUM THERAPEUTICS, INC. INDUCEMENT GRANT PERFORMANCE SHARE Unit Agreement COVER SHEET Definium Therapeutics, Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants performance share units (the “PSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the

Definium Therapeutics, Inc. Incentive Compensation Recoupment Policy Definium Therapeutics inc. Incentive Compensation Recoupment Policy Form of Covered Officer Acknowledgment Agreed and Acknowledged:

Exhibit 97.1 Definium Therapeutics, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Definium Therapeutics, Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), has determined that it is in the best interests of the Company to adopt this Incentive Compensation Recoupment Policy (this “Policy”) prov

DEFINIUM THERAPEUTICS, INC. Insider Trading Policy CERTIFICATION

Exhibit 19.1 DEFINIUM THERAPEUTICS, INC. INSIDER TRADING POLICY As amended and restated, effective April 11, 2025 Doc. No. P-CG-002 Rev. No. 004 Effective: 04/11/25 I. Introduction During the course of your employment with or service to Definium Therapeutics, Inc. (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the C

EX-99.1

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.

INDEMNIFICATION AGREEMENT

Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) AND CONTAINS PERSONAL INFORMATION. INDEMNIFICATION AGREEMENT THE AGREEMENT is made with effect on the day of . BETWEEN: DEFINIUM THERAPEUTICS, INC., a company incorporated under the Business Corporations Act (British Columbia) (hereinafter referred to as “Definium”) A

DEFINIUM THERAPEUTICS, INC. Inducement AWARD NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET

Exhibit 10.23 DEFINIUM THERAPEUTICS, INC. Inducement AWARD NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Definium Therapeutics, Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting a

Definium Therapeutics, Inc. – Subsidiaries 21.1 (List of Subsidiaries)

Exhibit 21.1 Definium Therapeutics, Inc. – Subsidiaries 21.1 (List of Subsidiaries) Subsidiary Jurisdiction of Incorporation Definium Therapeutics US, Inc. Delaware Healthmode, Inc. Delaware

DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN RESTRICTED SHARE Unit Agreement COVER SHEET

Exhibit 10.22 DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN RESTRICTED SHARE Unit Agreement COVER SHEET Definium Therapeutics, Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants restricted share units (the “RSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject

DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Definium Therapeutics, Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securities

Insert name and address of transferee

Exhibit 4.2 C0000000230 | M DEFINIUM THERAPEUTICS, INC. Shares * * * * 0 * * * * * * * * ** * * * * 0 * * * * * * * ** * * * * * 0 * * * * * * ** * * * * * * 0 * * * * * ** * * * * * * * 0 * * * * * 00000000 Number A BRITISH COLUMBIA COMPANY THIS CERTIFIES THAT**SPECIMEN24477V10500000000MIND*MEDICINE*(MINDMED)*INC.zero****SPECIMEN24477V10500000000MIND*MEDICINE*(MINDMED)*INC.zero****SPECIMEN24477V1

PART I PART II PART III PART IV

sign UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Definium T

AMENDED AND RESTATED ARTICLES MIND MEDICINE (MINDMED) INC. DEFINIUM THERAPEUTICS, INC. BUSINESS CORPORATIONS ACT BRITISH COLUMBIA

Exhibit 3.1 Pursuant to a Notice of Alteration filed on January 9, 2026, Mind Medicine (MindMed) Inc. changed its name to Definium Therapeutics, Inc. AMENDED AND RESTATED ARTICLES OF MIND MEDICINE (MINDMED) INC. DEFINIUM THERAPEUTICS, INC. BUSINESS CORPORATIONS ACT BRITISH COLUMBIA LEGAL1:106604724.1 Table of Contents Page Article 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Business Corporations Act

DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET

Exhibit 10.21 DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Definium Therapeutics, Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the

DEFINIUM THERAPEUTICS, INC. 2024 EMPLOYEE SHARE PURCHASE PLAN

Exhibit 10.13 DEFINIUM THERAPEUTICS, INC. 2024 EMPLOYEE SHARE PURCHASE PLAN 1. PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Affiliates may be given an opportunity to purchase Common Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. In addition, the Plan p

Equity Compensation Initial grants to newly appointed directors to be available for grant following approval of the Company’s 2025 Equity Incentive Plan at the Company’s 2025 Annual Meeting of Shareholders

Exhibit 10.9 Definium Therapeutics, Inc. Non-Employee Director Compensation Policy Effective as of May 8, 2025 Amended January 28, 2026 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Definium Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described

SECOND Amendment to Loan and security agreement

Exhibit 10.8 SECOND Amendment to Loan and security agreement This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of October 15, 2025, by and among MIND MEDICINE (MINDMED) INC., a corporation incorporated under the laws of the Province of British Columbia (“Borrower Representative”), MIND MEDICINE, INC., a Delaware corporation (“MindMed DE”) and HEALTHMODE, IN

DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN

Exhibit 10.20 DEFINIUM THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its shareholders and other important stakeholders, including i

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation

Notice of Articles

Exhibit 3.1 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies KERRY TAYLOR Notice of Articles BUSINESS CORPORATIONS ACT This Notice of Articles was issued by the Registrar on: January 9, 2026

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2026 Definium Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation

Corporate Presentation January 2026

Corporate Presentation January 2026 This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc.

CERTIFICATE OF

Exhibit 3.2 Number: BC0886671 CERTIFICATE OF CHANGE OF NAME BUSINESS CORPORATIONS ACT I Hereby Certify that MIND MEDICINE (MINDMED) INC. changed its name to DEFINIUM THERAPEUTICS, INC. on January 9, 2026 at 04:58 PM Pacific Time. Issued under my hand at Victoria, British Columbia On January 9, 2026 KERRY TAYLOR Registrar of Companies Province of British Columbia Canada ELECTRONIC CERTIFICATE

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Exhibit 99.1 MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting at the 44th Annual J.P. Morgan Healthcare Conference

Part Ii - OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind M

MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT PERFORMANCE SHARE Unit Agreement COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants performance share units

Exhibit 10.1 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT PERFORMANCE SHARE Unit Agreement COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants performance share units (the “PSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the

MindMed Reports Q3 2025 Financial Results and Business Updates -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- --Anticipated topli

Exhibit 99.1 MindMed Reports Q3 2025 Financial Results and Business Updates - Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)- -Anticipated topline data readout from first Phase 3 study of MM120 ODT in MDD (Emerge) accelerated to mid-2026, aligning with the anticipated initiation of s

Corporate Presentation November 2025

Corporate Presentation November 2025 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporati

Security Type

Calculation of Filing Fee Tables S-3 Mind Medicine (MindMed) Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Exhibit 99.2 Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering NEW YORK, October 29, 2025 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 18,375,000 common shar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 MIND MEDICINE (M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco

Mind Medicine (MindMed) Inc. 18,375,000 Common Shares (no par value per share) Underwriting Agreement

Exhibit 1.1 Final Version Mind Medicine (MindMed) Inc. 18,375,000 Common Shares (no par value per share) Underwriting Agreement New York, New York October 29, 2025 Jefferies LLC Leerink Partners LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed on Schedule I hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Leerink Partners LLC 1301 Avenue of th

18,375,000 Common Shares Mind Medicine (MindMed) Inc.

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-280548 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 28, 2024) 18,375,000 Common Shares Mind Medicine (MindMed) Inc. We are offering 18,375,000 common shares, without par value, at a public offering price of $12.25 per share. Our common shares are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “MNMD”

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Exhibit 99.1 Mind Medicine (MindMed) Inc. Announces Proposed Public Offering NEW YORK, October 29, 2025 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to

SUBJECT TO COMPLETION, DATED OCTOBER 29, 2025

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Corporate Presentation October 2025

Exhibit 99.1 Corporate Presentation October 2025 2 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construe d a s a p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 MIND MEDICINE (M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2025 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio

144

144 0001897557 XXXXXXXX LIVE 0001813814 MIND MEDICINE (MINDMED) INC. 001-40360 One World Trade Center, Suite 8500 New York NY 10007 (212) 220-6633 ROBERT B BARROW Officer Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 25797 252106.34 76087943 09/25/2025 NASDAQ Common 09/25/2025 Restricted stock vesting under a registered pl

144

144 0001331843 XXXXXXXX LIVE 0001813814 MIND MEDICINE (MINDMED) INC. 001-40360 One World Trade Center, Suite 8500 New York NY 10007 (212) 220-6633 MARK SULLIVAN Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 11278 110216.51 76087943 09/25/2025 NASDAQ Common 09/25/2025 Restricted stock vesting under a registered plan Issuer N

144

144 0001897618 XXXXXXXX LIVE 0001813814 MIND MEDICINE (MINDMED) INC. 001-40360 One World Trade Center, Suite 8500 New York NY 10007 (212) 220-6633 DANIEL ROLLINGS KARLIN Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 7704 75288.88 76087943 09/25/2025 NASDAQ Common 09/25/2025 Restricted stock vesting under a registered plan I

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 04, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporat

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) The Ph

Exhibit 99.1 Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administratio

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

Executive Employment Agreement, effective July 30, 2025, between Mind Medicine (MindMed) Inc. and Daniel Karlin, M.D.

Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Daniel Karlin M.D. (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement dated November 9, 2022, between the Company and Executive (the “Prior

Part Ii - OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medici

Executive Employment Agreement, effective July 30, 2025, between Mind Medicine (MindMed) Inc. and Mark R.Sullivan.

Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Mark R. Sullivan (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement dated April 13, 2023, between the Company and Executive (the “Prior Agr

Form of Option Agreement granted as an Inducement Award.

Exhibit 10.10 MIND MEDICINE (MINDMED) INC. Inducement AWARD NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting

Executive Employment Agreement, effective as of May 27, 2025, between Mind Medicine (MindMed) Inc. and Brandi L.Roberts.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective May 27, 2025 (the “Effective Date”), by and between Brandi L. Roberts (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to th

Corporate Presentation August 2025

Corporate Presentation August 2025 This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc.

Executive Employment Agreement, effective July 30, 2025, between Mind Medicine (MindMed) Inc. and Robert Barrow.

Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Robert Barrow (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”), and supersedes in its entirety the Executive Employment Agreement between the Company and Executive dated November 9, 2022 (the “Prior Agreem

MindMed Reports Q2 2025 Financial Results and Business Updates --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data fr

Exhibit 99.1 MindMed Reports Q2 2025 Financial Results and Business Updates -Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)- -Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD an

Executive Employment Agreement, effective July 30, 2025, between Mind Medicine (MindMed) Inc. and Matt Wiley.

Exhibit 10.9 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective July 30, 2025 (the “Effective Date”), by and between Matthew Wiley (the “Executive”) and Mind Medicine (MindMed) Inc. (the “Company”) and supersedes in its entirety the Executive Employment Agreement dated March 17, 2025 between the Company and Executive (the “Prior Agreement

Form of Restricted Share Unit Award Agreement to Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan.

Exhibit 99.3 MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN RESTRICTED SHARE Unit Agreement COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants restricted share units (the “RSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subjec

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mind Medicine (MindMed) Inc.

As filed with the Securities and Exchange Commission on June 20, 2025

As filed with the Securities and Exchange Commission on June 20, 2025 Registration No.

Form of Stock Option Award Agreement to Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan.

Exhibit 99.2 MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT COVER SHEET Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to th

Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan.

MIND MEDICINE (MINDMED) INC. 2025 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its shareholders and other important stakeholders, including its employees

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Approval of Mind Medicine (MindMed) Inc. 2025 Equity Incentive Plan Item 5.07 Submis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

Exhibit 99.1 MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer NEW YORK, May 27, 2025 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Mind Medicine (MindM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (

Executive Employment Agreement, dated as of March 17, 2025, between Mind Medicine (MindMed) Inc. and Matthew T. Wiley.

Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective March 17, 2025 (the “Effective Date”), by and between Matthew Wiley (the “Executive”) and Mind Medicine (MindMed), Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate the Executive for Executive’s personal services to the

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated

Exhibit 99.1 MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates -Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026- -Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week top

Part Ii - OTHER INFORMATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medic

Form of Restricted Share Unit Award Agreement granted as an Inducement Award.

Exhibit 10.3 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT RSU AWARD AGREEMENT This RSU Award Agreement is entered into between Mind Medicine (MindMed) Inc. (the "Corporation") and the RSU Holder named below. Your Award has been granted as an inducement that is material to your employment with the Corporation pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora

Form of Performance Share Unit Award Agreement to Performance and Restricted Share Unit Plan.

Exhibit 10.1 MIND MEDICINE (MINDMED) INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT This PSU Award Agreement (the “PSU Award Agreement”) is entered into between Mind Medicine (MindMed) Inc. (the “Corporation”) and the Participant named below pursuant to the Performance and Restricted Share Unit Plan of the Corporation (the "Plan") effective March 7, 2023, as

Form of Performance Share Unit Award Agreement granted as an Inducement Award.

Exhibit 10.2 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT PERFORMANCE SHARE UNIT AWARD AGREEMENT This PSU Award Agreement (the “PSU Award Agreement”) is entered into between Mind Medicine (MindMed) Inc. (the “Corporation”) and the Participant named below. The PSUs (as defined below) have been granted to the Participant as an inducement that is material to the Participant’s employment with the Cor

Form of Option Agreement granted as an Inducement Award.

Exhibit 10.4 MIND MEDICINE (MINDMED) INC. INDUCEMENT GRANT NONSTATUTORY STOCK OPTION AGREEMENT Your Option has been granted as an “inducement” award pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4) and not pursuant to the Mind Medicine (MindMed) Inc. Stock Option Plan (the “Plan”) or any equity incentive plan of the Corporation, as an inducement that is material

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medici

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th

First Amendment to Loan and Security Agreement, dated April 18, 2025, by and among Mind Medicine (MindMed) Inc., certain of its subsidiaries party thereto, K2 HealthVentures LLC and Ankura Trust Company, LLC.

Exhibit 10.1 CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST Amendment to Loan and security agreement This FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 18, 2025 (the “Restatement Effective Date”), by and among MIND MEDIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 Mind Medicine (Min

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsber

Exhibit 99.1 MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between MM120 Orally Disintegrating Tablet (ODT) 100 µg and placebo - - Emerge builds o

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week t

Exhibit 99.1 MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates -First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama- -On track to initiate Emerge, the first Phase 3 study of MM120 ODT

Description of Capital Stock of Mind Medicine (MindMed) Inc.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Mind Medicine (MindMed) Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securitie

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo

Insider Trading Policy

MIND MEDICINE (MINDMED) INC. INSIDER TRADING POLICY As amended and restated, effective July 25, 2022 Doc. No. P-CG-002 Rev. No. 002 Effective: 07/25/2022 I. Introduction During the course of your employment, directorship or consultancy with Mind Medicine (MindMed) Inc. (the “Company”), you may receive important information that is not yet publicly available (“inside information”) about the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine (

EX-99

EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC Aperio Group, LLC BlackRock Asset Management Canada Limited BlackRock (Netherlands) B.V. BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC *Entity ben

EX-24

EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from base

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Panorama builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 and will be conducted at sites in the US and Europe - - Topline data from the 12-week double-blind period anticipated in the second half of 2026 - NEW YORK – Mind Medicine (MindMed) Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio

Corporate Presentation January 2025

Exhibit 99.1 Corporate Presentation January 2025 Corporate Presentation | January 2025 This presentation (the “Presentation”) has been prepared by Mind Medicine ( MindMed ) Inc. (“ MindMed ”, the “Company”, “we”, “our” or “us) solely for informational purposes. This Presentation does not constitute an offering of , o r a solicitation of an offer to purchase, securities of MindMed and under no circ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporatio

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Ha

Exhibit 99.1 MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo - - Study builds on p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporati

MNMD / Mind Medicine (MindMed) Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 60255C885 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro

MNMD / Mind Medicine (MindMed) Inc. / BlackRock, Inc. Passive Investment

SC 13G 1 ca60255c8850110824.txt ca60255c8850110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MIND MEDICINE (MINDMED) INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) BPQYY97 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropria

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind M

Form of Pre-Funded Warrant

Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Warrant No. [●] Number of Shares: [●] (subject to adjustment) Original Issue Date: October [●], 2024 Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

MindMed Reports Third Quarter 2024 Financial Results and Business Updates --On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline

Exhibit 99.1 MindMed Reports Third Quarter 2024 Financial Results and Business Updates -On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026- -On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge s

MNMD / Mind Medicine (MindMed) Inc. / BlackRock, Inc. Passive Investment

SC 13G 1 ca60255c8850102224.txt ca60255c8850102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MIND MEDICINE (MINDMED) INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) BPQYY97 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropria

Up to 5,497,506 Common Shares Offered by the Selling Stockholders

Filed pursuant to Rule 424(b)(3)  Registration No. 333-278468 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 30, 2024) Up to 5,497,506 Common Shares Offered by the Selling Stockholders This prospectus supplement supplements the information contained in the prospectus dated April 30, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (Registration No. 333-278468

Calculation of Filing Fee Tables Form 424(b)(7) (Form Type) MindMed (Mind Medicine) Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(7) (Form Type) MindMed (Mind Medicine) Inc.

Up to 8,000,000 Common Shares Offered by the Selling Stockholders

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(7)  Registration No. 333-280548 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 28, 2024) Up to 8,000,000 Common Shares Offered by the Selling Stockholders This prospectus supplement relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus supplement under the caption “Selling Stockholders,” of up to 8

Form of Pre-Funded Warrant

Exhibit 4.1 Final Form NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT

Amendment No. 1 to the Registration Rights Agreement, dated as of October 17, 2024, by and among Mind Medicine (MindMed) Inc., Commodore Capital Master LP and Deep Track Biotechnology Master Fund, LTD.

Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO THE REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 to the Registration Rights Agreement (this “Amendment No. 1”) is made and entered into as of October 17, 2024, by and between Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each of the several purchasers s

Exchange Agreement, dated as of October 17, 2024, by and among Mind Medicine (MindMed) Inc., Commodore Capital Master LP and Deep Track Biotechnology Master Fund, LTD.

Exhibit 10.1 Execution Version October 17, 2024 Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 Re: Warrant Exchange Agreement Ladies and Gentlemen: This letter agreement (this “Agreement”) confirms the agreement of Mind Medicine (MindMed) Inc. (the “Company”), and the holders of the common shares, without par value, of the Company listed on Schedule I attached he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 MIND MEDICINE (M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco

Separation Agreement between Schond Greenway and Mind Medicine (MindMed) Inc., dated May 3, 2024, amended May 28, 2024

Exhibit 10.3 SEPARATION AGREEMENT CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. May 3, 2024 Amended May 28, 2024 Schond Greenway [***] [***] Re: Separation Agreement Dear Schond: This Agreement (the “Agreement”) sets forth the terms and conditions of your separat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 MIND MEDICINE (MI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40360 Mind Medici

Notice of Articles, Incorporated on July 26, 2010, effective as of July 30, 2024.

EX-3.2 2 mnmd-ex32.htm EX-3.2 Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the

MindMed Reports Second Quarter 2024 Financial Results and Business Updates --Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating table

Exhibit 99.1 MindMed Reports Second Quarter 2024 Financial Results and Business Updates -Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024- -Expanding pipeline with MM120 ODT clinical program in Major Dep

Form of Pre-Funded Warrant

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES Warrant No. [·] Number of Shares: [·] (subject to adjustment) Original Issue Date: [·], 2024 Mind Medicine (MindMed) Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

9,285,511 Common Shares Pre-Funded Warrants to Purchase 1,428,775 Common Shares MindMed (Mind Medicine) Inc.

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-280548 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 28, 2024) 9,285,511 Common Shares Pre-Funded Warrants to Purchase 1,428,775 Common Shares MindMed (Mind Medicine) Inc. We are offering 9,285,511 common shares, without par value, at a public offering price of $7.00 per share and, to certain investors, pre-funded warrants

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Exhibit 99.1 Mind Medicine (MindMed) Inc. Announces Proposed Public Offering NEW YORK, August 9, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain

Corporate Presentation August 2024

Exhibit 99.3 Corporate Presentation August 2024 Corporate Presentation | August 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine ( MindMed ) Inc. (“ MindMed ”, the “Company”, “we”, “our” or “us) solely for informational purposes. This Presentation does not constitute an offering of , o r a solicitation of an offer to purchase, securities of MindMed and unde

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Exhibit 99.2 Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering NEW YORK, August 9, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MIND MEDICINE (MIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp

Calculation of Filing Fee Tables (Form Type) Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Mind Medicine (MindMed) Inc.

Underwriting Agreement by and between Mind Medicine (MindMed) Inc. and Leerink Partners LLC and Evercore Group L.L.C., as representatives of the underwriters named therein, dated August 9, 2024.

Exhibit 1.1 Mind Medicine (MindMed) Inc. 9,285,511 Common Shares (no par value per share) Pre-Funded Warrants to Purchase 1,428,775 Common Shares Underwriting Agreement New York, New York August 9, 2024 Leerink Partners LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed on Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New Y

SUBJECT TO COMPLETION, DATED AUGUST 9, 2024

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

As filed with the Securities and Exchange Commission on June 28, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 28, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. Employee Share Purchase Plan

Exhibit 99.5 MIND MEDICINE (MINDMED) INC. 2024 EMPLOYEE SHARE PURCHASE PLAN 1.             PURPOSE. (a)           The Plan provides a means by which Eligible Employees of the Company and certain designated Affiliates may be given an opportunity to purchase Common Shares. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Share Purchase Plan. I

As filed with the Securities and Exchange Commission on June 28, 2024

As filed with the Securities and Exchange Commission on June 28, 2024 Registration No.

Sales Agreement, dated as of June 28, 2024, by and between Mind Medicine (MindMed) Inc. and Leerink Partners LLC

Exhibit 1.2 Mind Medicine (MindMed) Inc. Common Shares (no par value per share) Sales Agreement June 28, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MIND MEDICINE (MINDM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MIND MEDICINE (MINDMED) INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) Mind Medicine (MindMed) Inc.

Form of Indenture.

Exhibit 4.4 INDENTURE DATED AS OF           , 20 BETWEEN MIND MEDICINE (MINDMED) INC. as Issuer, AND as Trustee    Providing for Issuance of Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) -Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on

Exhibit 99.1 MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) -Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- NEW YORK, June 20, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpora

MindMed Reports First Quarter 2024 Financial Results and Business Updates --Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12

Exhibit 99.1 MindMed Reports First Quarter 2024 Financial Results and Business Updates -Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment- -The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medic

Up to 13,497,506 Common Shares Offered by the Selling Stockholders

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(3)  Registration No. 333-278468 PROSPECTUS Up to 13,497,506 Common Shares Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 13,497,506 of our common shares, no par value per share (the “common

Up to 13,497,506 Common Shares Offered by the Selling Stockholders

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(3)  Registration No. 333-278468 PROSPECTUS Up to 13,497,506 Common Shares Offered by the Selling Stockholders This prospectus relates to the offer and resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 13,497,506 of our common shares, no par value per share (the “common

Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007

Mind Medicine (MindMed) Inc. One World Trade Center Suite 8500 New York, NY 10007 April 26, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Mind Medicine (MindMed) Inc. Registration Statement on Form S-3 Filed April 2, 2024 File No. 333-278468 Request for Acceleration of

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a

LETTER

United States securities and exchange commission logo April 9, 2024 Robert Barrow Chief Executive Officer Mind Medicine (MindMed) Inc.

As filed with the Securities and Exchange Commission on April 2, 2024

S-3 Table of Contents As filed with the Securities and Exchange Commission on April 2, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Form S-3 (Form Type) Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Sha

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2024 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) British Columbia 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation)

MindMed Announces Voluntary Delisting from Cboe Canada All Common shares will remain listed on Nasdaq

Exhibit 99.1 MindMed Announces Voluntary Delisting from Cboe Canada All Common shares will remain listed on Nasdaq NEW YORK, April 1, 2024 -(BUSINESS WIRE)- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected t

MNMD / Mind Medicine (MindMed) Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Mind Medicine (MindMed) Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 60255C885 (CUSIP Number) March 11, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

MNMD / Mind Medicine (MindMed) Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Underwriting Agreement, dated March 7, 2024, by and between Mind Medicine (MindMed) Inc. and Leerink Partners LLC and Cantor Fitzgerald & Co.

Exhibit 1.1 Mind Medicine (MindMed) Inc. 16,666,667 Common Shares (no par value per share) Underwriting Agreement New York, New York March 7, 2024 Leerink Partners LLC Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed on Schedule I hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 c/o Cantor Fitzgerald & Co. 110 East 59th S

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

EX-99.1 Exhibit 99.1 Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement NEW YORK, March 7, 2024 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the prici

Form of Securities Purchase Agreement, dated as of March 7, 2024 between Mind Medicine (MindMed) Inc. and the Investors

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 7, 2024, by and between MIND MEDICINE (MINDMED) INC., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser

Form of Registration Rights Agreement, dated as of March 7, 2024 between Mind Medicine (MindMed) Inc. and the Investors

EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 7, 2024, by and between Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collecti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (Mind

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo

16,666,667 Common Shares MindMed (Mind Medicine) Inc.

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-264648 Registration No. 333-277726 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 16, 2022) 16,666,667 Common Shares MindMed (Mind Medicine) Inc. We are offering 16,666,667 common shares, no par value per share, at a public offering price of $6.00 per share. Our common shares are listed on the Nasdaq Global Select Market

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-3 MIND MEDICINE (MINDMED) INC.

MINDMED RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION AND ANNOUNCES POSITIVE 12-WEEK DURABILITY DATA FROM PHASE 2B STUDY OF MM120 FOR GENERALIZED ANXIETY DISORDER -A single oral administration of MM120 100 µg met its key secondary endpoint and mainta

EX-99.1 Exhibit 99.1 THURSDAY MARCH 7, 2023, 6:00 AM EST MINDMED RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION AND ANNOUNCES POSITIVE 12-WEEK DURABILITY DATA FROM PHASE 2B STUDY OF MM120 FOR GENERALIZED ANXIETY DISORDER -A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 we

Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees

EX-99.2 Exhibit 99.2 MM120 for GAD Investor Presentation March 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (Mind

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo

Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees

EX-99.1 Exhibit 99.1 MM120 for Generalized Anxiety Disorder (GAD) Phase 2b Full Topline Data ODT PK Bridging Study Breakthrough Therapy Designation March 2024 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. None of MindMed, its affiliates or any of their respective

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (Mind

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Mind Medicine (MindMed) Inc. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582538 (State or Other Jurisdiction of Incorpo

As filed with the Securities and Exchange Commission on March 7, 2024

S-3MEF As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medicine (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MIND MEDICINE (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc

MindMed Reports 2023 Financial Results and Business Updates --Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in

Exhibit 99.1 MindMed Reports 2023 Financial Results and Business Updates -Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)- -Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half

Policy Relating to Recovery of Erroneously Awarded Compensation

Exhibit 97.1 Mind Medicine (MindMed) Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentive Compensation Recoupment Poli

Form of Mind Medicine (MindMed) Inc. Common Share Certificate.

Exhibit 4.2 C0000000230 | M Number 00000000 THIS CERTIFIES THAT MIND MEDICINE (MINDMED) INC. A BRITISH COLUMBIA COMPANY Shares * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * IS THE REGISTERED HOLDER OF FULLY PAID AND NON-ASSESSABLE COMMON SHARES WITHOUT PAR VALUE IN THE CAPITAL OF MIND MEDICINE (MINDMED) I

Notice of Articles, Incorporated on July 26, 2010, effective as of August 18, 2023.

Exhibit 3.2 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 Cover Sheet MIND MEDICINE (MINDMED) INC. Confirmation of Service Form Filed: Notice of Change of Address Date and Time of Filing: August 17, 2023 04:53 PM Pacific Time Effective Date: Specified Date and Time of Filing: August

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Mind Medicine (MindMed) Inc. (the “Company”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description of our securitie

MindMed Announces Business Update and Anticipated Milestones for 2024 -- Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts

Exhibit 99.1 MindMed Announces Business Update and Anticipated Milestones for 2024 - Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program - - Proof-of-Concept study evaluating repeated sub-percept

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MIND MEDICINE (MI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 MIND MEDICINE (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as specified in its Charter) British Columbia, Canada 001-40360 98-1582438 (State or other jurisdiction of inc

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder – Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks afte

EX-99.1 Exhibit 99.1 MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder – Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, represe

Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. Any trademarks included herein are the property of the owners thereof and are used for

EX-99.2 Exhibit 99.2 MM-120 for Generalized Anxiety Disorder (GAD) Phase 2b Topline Data December 2023 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not b

Logo Third Quarter 2023 Financial Results and Business Update November 2, 2023

Exhibit 99.2 Logo Third Quarter 2023 Financial Results and Business Update November 2, 2023 Disclaimer This presentation (the “Presentation”) has been preparedby Mind Medicine(MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representat

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 – – MM-

Exhibit 99.1 MindMed Reports Third Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Cash and cash equivalents of $117.7 million at September 30, 202

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Inc

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) New York 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (Commi

K2 HealthVentures LLC Loan and Security Agreement

CERTAIN PORTIONS OF THIS EXHIBIT (INDICATED BY “[***]”) HAVE BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Company Logo MindMed Investor Presentation August 2023

Exhibit 99.1 Company Logo MindMed Investor Presentation August 2023 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes a

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Mind Medicine (MindMed) Inc. (Exact name of Registrant as Specified in Its Charter) New York 001-40360 98-1582438 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MIND MEDICINE (MIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40360 Mind Medici

Non-Employee Director Compensation Policy, amended as of June 8, 2023

Exhibit 10.2 Mind Medicine (MindMed) Inc. Non-Employee Director Compensation Policy Effective as of June 1, 2022 Amended August 11, 2022 Amended June 8, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Mind Medicine (MindMed) Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the

Directors' Deferred Share Unit Plan, amended as of June 8, 2023

Exhibit 10.3 DIRECTORS’ DEFERRED SHARE UNIT PLAN EFFECTIVE AS OF APRIL 16, 2021 AMENDED AS OF JUNE 8, 2023 1. DEFINITIONS a. When used herein, the following terms shall have the following meanings: i. “Associated Company” means any subsidiary or affiliate of the Company. ii. “Administrator” means the Board or, if so delegated by the Board to administer the Plan, the Compensation Committee, or any

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concep

Exhibit 99.1 MindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Entered into exclusiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MIND

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 MIND MEDICINE (MIND

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo

MindMed Investor Presentation Investor Day 2023: MM-120 for Generalized Anxiety Disorder

Exhibit 99.1 MindMed Investor Presentation Investor Day 2023: MM-120 for Generalized Anxiety Disorder Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors,

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 MIND MEDICINE (MIND

DEFA14AJune 16 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MIND MEDICINE (MIND

DEFA14AJune 15 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

MindMed Adjourns Annual General Meeting of Shareholders Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’

Exhibit 99.1 MindMed Adjourns Annual General Meeting of Shareholders Meeting Will Resume on Wednesday, June 21, 2023 Believes FCM Has Made Deliberate Efforts to Prevent Quorum from Being Achieved MindMed Encourages Shareholders to Vote FOR All Six of the Company’s Director Candidates on the WHITE Universal Proxy Card NEW YORK, June 15, 2023 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MIND MEDICINE (MIND

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

INVESTOR PRESENTATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

SUPPLEMENTAL INVESTOR PRESENTATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

LETTER TO SHAREHOLDERS

Q
6ĥ
 ĥ 
ĥ¹ Å
 
ĥ ĥĥ āE- Cĥ  ĥ 2ĥ´ĥ ¬ - Cĥĥ $- ĥ

$Ä
ĥ Û

ĥ  
ĥĥ >
1ĥ @ĥ ĥÕ
 ĥë Jz ĥ
ĥ

 ĥĥ
ĥ ĥ 

ĥ
ĥ


ĥ
 ĥ 
ĥˆ/Ĥñĥ È
ĥ½
#ĥ° ĥ ĥª
9 
ăĥ ?ó‰ĥĥ 
ĥ ĥ R ĥĥĥ ĥ(
ĥ# ĥ
9
,

ĥ Âkĥ
9
w
ĥ

$ĥå ĥ 
ĥÆÒĥĥ 
ĥ  X
ĥ   Gĥ$éiĥ #

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 mnmdgreenleafprmay2.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 MIND MEDICINE (MINDM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor

MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-402 –

Exhibit 99.1 MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-402 – NEW YORK, May 24, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing nov

INVESTOR PRESENTATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 –

Exhibit 99.1 MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 – NEW YORK, May 17, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 MIND MEDICINE (MINDM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 MIND MEDICINE (MINDMED) INC. (Exact name of Registrant as Specified in Its Charter) British Columbia, Canada 001-40360 98-1582438 (State or Other Jurisdiction of Incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

EXHIBIT 1

Drug Name Active Ingredient Approval Date FDA-approved use on approval date* Prepopik sodium picosulfate, magnesium oxide and citric acid 7/16/2012 To help cleanse the colon in adults preparing for colonoscopy.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

LETTER TO STOCKHOLDERS, DATED MAY 5, 2023

FCM FCM MM HOLDINGS, LLC May 5, 2023 Dear Fellow MindMed Shareholders, FCM MM Holdings, LLC and its affiliates (collectively, “FCM”) beneficially own 1,368,538 shares of Mind Medicine (MindMed) Inc.